Statins, Cholesterol and Cognitive Decline in Alzheimer's

Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Dementia Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Statins Tauopathies

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Karolinska Institutet

Stockholm, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients with AD and mixed dementia registered in SveDem and from SCREAM.

Exclusion criteria

All patients with a missing MMSE score at diagnosis date will be excluded from the analyses.
Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.

Treatment and study plan

STA 4783

Drug

Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date

Primary outcomes

Cognitive decline

Time frame: Through study completion, at least 1 year

The data on cognitive change will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

Region Stockholm

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Oct 10, 2024
Registry last updated: May 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed